Literature DB >> 2121737

Characterization of the adenosine deaminase-adenosine deaminase complexing protein binding reaction.

W P Schrader1, C A West, A D Miczek, E K Norton.   

Abstract

Glutaraldehyde-fixed membranes from rabbit kidney cortex were used to characterize binding of monomeric adenosine deaminase to the adenosine deaminase complexing protein. With the use of bovine adenosine deaminase it was shown that enzyme binding is a saturable, high affinity process. The K value for binding of the bovine enzyme was 11 nM. Maximum enzyme binding and rate of binding to a constant amount of membrane did not vary significantly from pH 5.0 to 9.5. Metal ions, with the exception of Hg2+, sulfhydryl reagents, and other proteins had little or a slightly stimulatory effect on maximum binding. Mercuric ion inhibited binding. Using biotinylated bovine adenosine deaminase it was shown that purified rabbit, human, and monkey enzymes compete for binding sites on fixed membranes. The K values for the rabbit and human enzymes were 9 and 6 nM, respectively. Mouse or guinea pig adenosine deaminase did not bind to the membranes or compete with the biotinylated bovine enzyme for binding sites. The retention of characteristics required for binding by enzymes from rabbit, human, monkey, and calf tissues argues for biologic significance of the adenosine deaminase-complexing protein interaction. The basis for the apparent failure of rodent adenosine deaminase to bind to complexing protein remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121737

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells.

Authors:  Emilie C Lefort; Jonathan Blay
Journal:  Clin Exp Metastasis       Date:  2011-02-05       Impact factor: 5.150

2.  Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26.

Authors:  Holger K Eltzschig; Marion Faigle; Simone Knapp; Jorn Karhausen; Juan Ibla; Peter Rosenberger; Kirsten C Odegard; Peter C Laussen; Linda F Thompson; Sean P Colgan
Journal:  Blood       Date:  2006-05-02       Impact factor: 22.113

3.  Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells.

Authors:  Magis Mandapathil; Benedict Hilldorfer; Miroslaw J Szczepanski; Malgorzata Czystowska; Marta Szajnik; Jin Ren; Stephan Lang; Edwin K Jackson; Elieser Gorelik; Theresa L Whiteside
Journal:  J Biol Chem       Date:  2009-10-26       Impact factor: 5.157

4.  Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior.

Authors:  Ernest Y Tan; Michelle Mujoomdar; Jonathan Blay
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

5.  Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.

Authors:  Daniela Lamers; Susanne Famulla; Nina Wronkowitz; Sonja Hartwig; Stefan Lehr; D Margriet Ouwens; Kristin Eckardt; Jean M Kaufman; Mikael Ryden; Stefan Müller; Franz-Georg Hanisch; Johannes Ruige; Peter Arner; Henrike Sell; Juergen Eckel
Journal:  Diabetes       Date:  2011-05-18       Impact factor: 9.461

6.  The binding site of human adenosine deaminase for CD26/Dipeptidyl peptidase IV: the Arg142Gln mutation impairs binding to cd26 but does not cause immune deficiency.

Authors:  E Richard; F X Arredondo-Vega; I Santisteban; S J Kelly; D D Patel; M S Hershfield
Journal:  J Exp Med       Date:  2000-11-06       Impact factor: 14.307

7.  A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells.

Authors:  U V Wesley; A P Albino; S Tiwari; A N Houghton
Journal:  J Exp Med       Date:  1999-08-02       Impact factor: 14.307

Review 8.  DPP4 in Diabetes.

Authors:  Diana Röhrborn; Nina Wronkowitz; Juergen Eckel
Journal:  Front Immunol       Date:  2015-07-27       Impact factor: 7.561

Review 9.  Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma.

Authors:  Thomas Bogenrieder; Meenhard Herlyn
Journal:  Crit Rev Oncol Hematol       Date:  2002-10       Impact factor: 6.312

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.